Literature DB >> 17573443

Results of endoscopic surgery and intralesional steroid therapy for airway compromise due to tracheobronchial Wegener's granulomatosis.

S A R Nouraei1, R Obholzer, P W Ind, A D Salama, C D Pusey, F Porter, D J Howard, G S Sandhu.   

Abstract

BACKGROUND: Upper airway compromise due to tracheobronchial stenosis commonly occurs in patients with Wegener's granulomatosis (WG). There is at present no consensus on the optimal management of this life threatening condition.
OBJECTIVE: To assess the results of laryngo-tracheo-bronchoscopy, intralesional steroid therapy, laser surgery and dilatation in managing obstructive tracheobronchial WG.
METHODS: Records of 18 previously untreated stridulous patients with obstructive tracheobronchial WG, treated between 2004 and 2006, were prospectively recorded on an airway database and retrospectively reviewed. Information about patient and lesion characteristics and treatment details were recorded. Treatment progress was illustrated using a timeline plot, and intervention-free intervals were calculated with actuarial analysis.
RESULTS: There were nine males and the average age at presentation was 40 (16) years (range 13-74). There were 13 patients with tracheal and five with tracheal and bronchial lesions. The average tracheal lesion height was 8 (3) mm, located 23 (9) mm below the glottis. There were 1, 10 and 7 Myer-Cotton grade I, II and III lesions, respectively. Mean intervention-free interval following minimally invasive treatment was 26 (2.8) months. Following endobronchial therapy, the median intervention-free interval was 22 months (p>0.8 vs tracheal lesions). No patient required a tracheostomy or endoluminal stenting.
CONCLUSIONS: Intralesional steroid therapy and conservative endoluminal surgery is an effective strategy for treating airway compromise due to active tracheal and bronchial WG, obviating the need for airway bypass or stenting. We recommend the combination of endotracheal dilatation, conservative laser surgery and steroid therapy as the standard of care for treating airway compromise due to obstructive tracheobronchial WG.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17573443     DOI: 10.1136/thx.2007.078915

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  6 in total

Review 1.  [S1 guidelines Diagnostics and treatment of ANCA-associated vasculitis].

Authors:  Jan Henrik Schirmer; Peer M Aries; Kirsten de Groot; Bernhard Hellmich; Julia U Holle; Christian Kneitz; Ina Kötter; Peter Lamprecht; Ulf Müller-Ladner; Eva Reinhold-Keller; Christof Specker; Michael Zänker; Frank Moosig
Journal:  Z Rheumatol       Date:  2017-11       Impact factor: 1.372

2.  Finding balance between minimally invasive surgery and laryngotracheal resection in the management of adult laryngotracheal stenosis.

Authors:  György B Halmos; Fréderique S A M Schuiringa; Dóra Pálinkó; Tom P van der Laan; Frederik G Dikkers
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-02-02       Impact factor: 2.503

3.  Life-Threatening Subglottic Stenosis of Granulomatosis with Polyangiitis: A Case Report.

Authors:  Jin An; Jae-Won Song
Journal:  Medicina (Kaunas)       Date:  2021-04-27       Impact factor: 2.430

Review 4.  Current and future prospects in the management of granulomatosis with polyangiitis (Wegener's granulomatosis).

Authors:  Ruth M Tarzi; Charles D Pusey
Journal:  Ther Clin Risk Manag       Date:  2014-04-17       Impact factor: 2.423

5.  Bronchoscopic local steroid spray to prevent bronchial tuberculosis-induced cicatricial bronchial stenosis: A case series.

Authors:  Daizo Yaguchi; Motoshi Ichikawa; Masato Shizu; Noriko Inoue; Daisuke Kobayashi; Naoyuki Imai
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

6.  Tracheobronchial Stenoses in Granulomatosis With Polyangiitis (Wegener's): A Report on 26 Cases.

Authors:  Charlotte Girard; Pierre Charles; Benjamin Terrier; Guillaume Bussonne; Pascal Cohen; Christian Pagnoux; Vincent Cottin; Jean-François Cordier; Loïc Guillevin
Journal:  Medicine (Baltimore)       Date:  2015-08       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.